Novartis' canakinumab gets an FDA rejection, but it raises guidance anyway
admin 18th October 2018 Uncategorised 0Novartis is raising its 2018 sales outlook, but canakinumab won’t help it hit the new target—at least not in the cardiovascular sales department.
More: Novartis' canakinumab gets an FDA rejection, but it raises guidance anyway
Source: fierce